Vickers Venture invests in U.K.'s Emergex as biotechs race to develop drug LESLIE SHAFFER, v2S3tj1hG38/XnXW_qCXh7I/AAAAAAAAGoM/Lr9j4nzjDwAKM9lZsLxTz3fniC8UpdB4gCLcBGAsYHQ/s320/https___s3-ap-northeast-1.amazonaws.com_psh-ex-ftnikkei-3937bb4_images_8_2_7_3_25653728-1-eng-GB_RTS35XT4.jpg" width="320" /> DealStreetAsia SINGAPORE -- As the new coronavirus spreads across the globe and devastates communities, companies are racing to develop a vaccine, with the U.K.'s Emergex becoming the latest to divert resources from other projects, including the development of a dengue fever vaccine, to work on COVID-19. The startup expects to have a vaccine ready for testing within two months, Lim Xinhong, director and analyst at Singapore-based venture capital firm Vickers Venture Partners told DealStreetAsia. Vickers Venture is an investor in Emergex. Lim, who has a doctorate in developmental biology from Stanford University, explained that traditionally, vaccines us...